Generate Biomedicines, Inc.
GENBBuy · Weight Up
ARK net-bought the stock and the price rose, increasing its portfolio weight.
Shares +20.7% · Market value +3.4% · Weight +0.01%p
| Date | Action | ETF | Shares | Close | Est. total |
|---|---|---|---|---|---|
| 26.07.10 | BUY | ARKG | 54,804 | $14.32 | $785.1K |
| 26.07.09 | BUY | ARKG | 57,462 | $15.72 | $903.3K |
| 26.07.08 | BUY | ARKG | 61,750 | $15.87 | $980.0K |
| 26.07.07 | BUY | ARKG | 44,170 | $16.22 | $716.4K |
| 26.07.06 | BUY | ARKG | 92,202 | $16.92 | $1.6M |
| 26.07.02 | BUY | ARKG | 26,483 | $17.41 | $461.1K |
| 26.07.01 | BUY | ARKG | 69,680 | $16.50 | $1.1M |
| 26.06.30 | BUY | ARKG | 27,949 | $16.87 | $471.5K |
| 26.06.29 | BUY | ARKG | 136,406 | $16.91 | $2.3M |
| 26.06.26 | BUY | ARKG | 63,768 | $16.47 | $1.1M |
| 26.06.25 | BUY | ARKG | 31,159 | $16.42 | $511.6K |
| 26.06.24 | BUY | ARKG | 50,900 | $16.23 | $826.1K |
| 26.06.23 | BUY | ARKG | 404 | $15.43 | $6.2K |
| 26.06.18 | BUY | ARKG | 15,435 | $14.49 | $223.7K |
| 26.06.17 | BUY | ARKG | 9,617 | $13.87 | $133.4K |
Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
Analyst Consensus
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Price Information
Trading Volume
Valuation
Financials
Profitability
Dividend
Technical
Generate Biomedicines utilizes machine learning and generative biology to discover and develop novel protein therapeutics. Their platform aims to create protein-based drugs, with current pipeline candidates including treatments for severe asthma and cancer. The company positions itself as an innovator in addressing complex therapeutic challenges beyond traditional methods.
AI-generated summary. Not investment advice.
Related ARK stocks
Explore companies with similar themes or neighboring ARK trading activity.